









Markets
/
Stocks
/
nasdaq-bsx
/

Boston Scientific Corp

BSX

View Detailed Chart

105.300USD

+0.380+0.36%

Market hours （ET）Quotes delayed by 15 min

155.76BMarket Cap

76.65P/E TTM



Boston Scientific Corp

105.300

+0.380+0.36%

Overview Company Financials

Financials

Intraday

30m

Today

+0.36%

5 Days

-0.86%

1 Month

-1.96%

6 Months

+2.87%

Year to Date

+17.89%

1 Year

+42.53%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 36 analysts

BUY

Current Rating

123.306

Target Price

17.52%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

Danaher Corp

DHR

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(6)

Neutral(2)

Buy(5)

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.211

Buy

RSI(14)

51.311

Neutral

STOCH(KDJ)(9,3,3)

47.896

Sell

ATR(14)

2.304

Low Volatility

CCI(14)

9.897

Neutral

Williams %R

60.180

Sell

TRIX(12,20)

0.109

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

106.026

Sell

MA10

105.468

Sell

MA20

104.545

Buy

MA50

103.736

Buy

MA100

101.614

Buy

MA200

97.841

Buy

News

Boston Sci Q2 Revenue Up 23%

Key PointsRevenue climbed to $5.06 billion in Q2 2025, up 23% from the prior year period and 3.4% above analyst expectations.Adjusted EPS reached $0.75 for Q2 2025, exceeding estimates for the quarter and adjusted EPS rose 21% year over year.

The Motley FoolMon, Jul 28

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.

Ticker SymbolBSX

CompanyBoston Scientific Corp

CEOMr. Michael F. (Mike) Mahoney

Websitehttps://www.bostonscientific.com/en-US/Home.html